| Budget Amount *help |
¥26,520,000 (Direct Cost: ¥20,400,000、Indirect Cost: ¥6,120,000)
Fiscal Year 2012: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2011: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2010: ¥10,530,000 (Direct Cost: ¥8,100,000、Indirect Cost: ¥2,430,000)
Fiscal Year 2009: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Research Abstract |
Assisted reproductive technology is the most appropriate management if a natural pregnancy fails to occur, and this is increasingly used in the treatment of both male and female infertility. However, fertilization is better in vivo than in vitro for male infertility. Clinically, testicular gene therapy may be useful to treat male infertility in the future because it is possible to promote spermatogenesis in male infertility patient. In this study, I tried to perform basic research to realize the gene therapy for male infertility. Although more genetic information about the molecular basis of spermatogenesis will be needed to apply gene therapy for male infertility, these informations may lead to new strategies for the clinical management and gene therapy will provides great benefits for the patients with male infertility in the future.
|
